Voyager Therapeutics (NASDAQ:VYGR) Receives Buy Rating from HC Wainwright

Voyager Therapeutics (NASDAQ:VYGR)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $30.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 431.91% from the company’s previous close.

A number of other research firms have also issued reports on VYGR. Leerink Partners initiated coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 target price on the stock. StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Sunday, November 10th. Wedbush decreased their target price on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. Finally, Leerink Partnrs raised Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $17.00.

Voyager Therapeutics Stock Down 9.3 %

NASDAQ VYGR opened at $5.64 on Thursday. The stock has a market cap of $308.11 million, a price-to-earnings ratio of 7.94 and a beta of 0.89. Voyager Therapeutics has a fifty-two week low of $5.59 and a fifty-two week high of $11.72. The business has a fifty day moving average of $6.62 and a 200-day moving average of $7.50.

Insider Buying and Selling at Voyager Therapeutics

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the transaction, the insider now directly owns 86,001 shares of the company’s stock, valued at $500,525.82. The trade was a 6.52 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 4.53% of the stock is owned by company insiders.

Institutional Investors Weigh In On Voyager Therapeutics

Several large investors have recently made changes to their positions in the business. Armistice Capital LLC boosted its position in Voyager Therapeutics by 11.3% during the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after purchasing an additional 528,000 shares during the period. Vanguard Group Inc. lifted its stake in shares of Voyager Therapeutics by 27.8% during the first quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock worth $30,087,000 after purchasing an additional 702,030 shares in the last quarter. Farallon Capital Management LLC boosted its position in shares of Voyager Therapeutics by 77.4% in the first quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company’s stock worth $21,339,000 after buying an additional 1,000,000 shares during the period. Great Point Partners LLC acquired a new stake in shares of Voyager Therapeutics in the second quarter valued at about $12,668,000. Finally, Erste Asset Management GmbH purchased a new stake in shares of Voyager Therapeutics during the 3rd quarter valued at about $6,192,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.